Skip to main content
Have a personal or library account? Click to login
Tyrosine kinase inhibitor treatment outcome in a single center cohort of chronic myeloid leukemia patients. The role of the T315I ABL kinase domain mutation Cover

Tyrosine kinase inhibitor treatment outcome in a single center cohort of chronic myeloid leukemia patients. The role of the T315I ABL kinase domain mutation

Revista Romana de Medicina de Laborator
Volume 21 (2013): Issue 1 (March 2013)
By: Delia Dima,  Adrian P. Trifa,  Mariana Paţiu,  Cristian S. Vesa,  Ioana C. Frinc,  Ljubomir Petrov and  Andrei Cucuianu  
Open Access
|Aug 2013
Authors

Authors

Delia Dima

Adrian P. Trifa

Mariana Paţiu

Cristian S. Vesa

Ioana C. Frinc

Ljubomir Petrov

Andrei Cucuianu

acucuianu@yahoo.com

DOI: https://doi.org/10.2478/rrlm-2013-0015 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Journal RSS Feed
Language: English
Page range: 29 - 37
Published on: Aug 8, 2013
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Chronic myeloid leukemia,
mutation,
T315I,
imatinib
Related subjects:
Life sciences,
Molecular biology,
Biochemistry,
Human biology,
Microbiology and virology

© 2013 Delia Dima, Adrian P. Trifa, Mariana Paţiu, Cristian S. Vesa, Ioana C. Frinc, Ljubomir Petrov, Andrei Cucuianu, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons License.

Volume 21 (2013): Issue 1 (March 2013)
Previous article
Next article